{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:02:00Z","timestamp":1792479720322,"version":"4.5.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Whether kidney transplant recipients who were treated for a malignant tumor before transplantation are at an increased risk of developing a tumor posttransplantation has not been adequately quantified and characterized.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We studied more than 270\u2009000 patients on whom pretransplant and posttransplant malignancy data were reported to the Collaborative Transplant Study. More than 4000 of these patients were treated for pretransplant malignancy. The posttransplant tumor incidence in these patients was compared to that in recipients without a pretransplant tumor. Cox regression, considering multiple confounders, was applied.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Significant increases in posttransplant tumor incidence with hazard ratio ranging from 2.10 to 5.47 (all <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) were observed for tumors in the site-specific pretransplant locations, suggesting tumor recurrences. There were also significantly increased de novo tumors in new locations with hazard ratio ranging from 1.28 to 1.89. Pretransplant basal cell carcinoma of the skin and male genital cancer were associated with significantly increased death-censored graft survival, suggesting impaired immune responsiveness against transplanted kidneys. Time interval from pretransplant tumor occurrence to transplantation and posttransplant mammalian target of rapamycin inhibitor treatment was not found to be of significant relevance in this study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Patients who experienced a pretransplant tumor are at significant risk of tumor recurrence, regardless of the length of interval between tumor treatment and transplantation. There is also some increased risk for de novo tumors, suggesting impaired immune surveillance. Impaired tumor immunity appears to extend to a lower rate of transplant rejection because patients with pretransplant tumors tended to show improved death-censored graft survival.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000002459","type":"journal-article","created":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T13:11:15Z","timestamp":1541855475000},"page":"581-587","source":"Crossref","is-referenced-by-count":25,"title":["Pretransplant Cancer in Kidney Recipients in Relation to Recurrent and De Novo Cancer Incidence Posttransplantation and Implications for Graft and Patient Survival"],"prefix":"10.1097","volume":"103","author":[{"given":"Christian","family":"Unterrainer","sequence":"first","affiliation":[{"name":"Institute of Immunology, Heidelberg University, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Opelz","sequence":"additional","affiliation":[{"name":"Institute of Immunology, Heidelberg University, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"D\u00f6hler","sequence":"additional","affiliation":[{"name":"Institute of Immunology, Heidelberg University, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caner","family":"S\u00fcsal","sequence":"additional","affiliation":[{"name":"Institute of Immunology, Heidelberg University, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20231002","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/j.1600-6143.2010.03181.x","article-title":"Comparison of the incidence of malignancy in recipients of different types of organ: a UK registry audit.","volume":"10","author":"Collett","year":"2010","journal-title":"Am J Transplant"},{"key":"R2-20231002","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1600-6143.2004.00450.x","article-title":"Cancer after kidney transplantation in the United States.","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"key":"R3-20231002","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/ndt\/gfw088","article-title":"Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.","volume":"31","author":"Opelz","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"R4-20231002","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/j.1600-6143.2007.01908.x","article-title":"Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients.","volume":"7","author":"Webster","year":"2007","journal-title":"Am J Transplant"},{"key":"R5-20231002","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2165\/00003495-200767080-00006","article-title":"Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.","volume":"67","author":"Gutierrez-Dalmau","year":"2007","journal-title":"Drugs"},{"key":"R6-20231002","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1432-2277.2006.00330.x","article-title":"Post-transplant de novo malignancies in renal transplant recipients: the past and present.","volume":"19","author":"Kauffman","year":"2006","journal-title":"Transpl Int"},{"key":"R7-20231002","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ijc.1319","article-title":"Second primary cancers after anogenital, skin, oral, esophageal and rectal cancers: etiological links?","volume":"93","author":"Hemminki","year":"2001","journal-title":"Int J Cancer"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"E57","DOI":"10.1503\/cmaj.110167","article-title":"Associations between first and second primary cancers: a population-based study.","volume":"184","author":"Nielsen","year":"2012","journal-title":"CMAJ"},{"key":"R9-20231002","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/TP.0000000000001192","article-title":"Outcomes of solid organ transplant recipients with preexisting malignancies in remission: a systematic review and meta-analysis.","volume":"101","author":"Acuna","year":"2017","journal-title":"Transplantation"},{"key":"R10-20231002","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1097\/TP.0000000000001659","article-title":"Association between pretransplant cancer and survival in kidney transplant recipients.","volume":"101","author":"Dahle","year":"2017","journal-title":"Transplantation"},{"key":"R11-20231002","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.trre.2013.01.004","article-title":"The Collaborative Transplant Study registry.","volume":"27","author":"Opelz","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"R12-20231002","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/ndt\/gft355","article-title":"When do we need competing risks methods for survival analysis in nephrology?","volume":"28","author":"Noordzij","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"R13-20231002","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.trre.2012.07.001","article-title":"New concepts and best practices for management of pre- and post-transplantation cancer.","volume":"26","author":"Campistol","year":"2012","journal-title":"Transplant Rev (Orlando)"},{"key":"R14-20231002","first-page":"14","article-title":"Evaluation of transplant candidates with pre-existing malignancies.","volume":"2","author":"Penn","year":"1997","journal-title":"Ann Transplant"},{"key":"R15-20231002","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/TP.0b013e3182637078","article-title":"Clinical practice guidelines on wait-listing for kidney transplantation: consistent and equitable?","volume":"94","author":"Batabyal","year":"2012","journal-title":"Transplantation"},{"key":"R16-20231002","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.","volume":"18","author":"Mathew","year":"2004","journal-title":"Clin Transplant"},{"key":"R17-20231002","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1600-6143.2012.04004.x","article-title":"Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer.","volume":"12","author":"Campbell","year":"2012","journal-title":"Am J Transplant"},{"key":"R18-20231002","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation.","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"key":"R19-20231002","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1681\/ASN.2005090993","article-title":"Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.","volume":"17","author":"Campistol","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R20-20231002","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"key":"R21-20231002","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/TP.0b013e3182247ae2","article-title":"Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.","volume":"92","author":"Alberu","year":"2011","journal-title":"Transplantation"},{"key":"R22-20231002","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.trre.2017.08.003","article-title":"Cancer recurrence after solid organ transplantation: a systematic review and meta-analysis.","volume":"31","author":"Acuna","year":"2017","journal-title":"Transplant Rev (Orlando)"},{"key":"R23-20231002","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/TP.0b013e31817fdddb","article-title":"Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant.","volume":"86","author":"Opelz","year":"2008","journal-title":"Transplantation"},{"key":"R24-20231002","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ajt.13593","article-title":"Recommendations for solid organ transplantation for transplant candidates with a pretransplant diagnosis of cutaneous squamous cell carcinoma, Merkel cell carcinoma and melanoma: a consensus opinion from the International Transplant Skin Cancer Collaborative (ITSCC).","volume":"16","author":"Zwald","year":"2016","journal-title":"Am J Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007890-201903000-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:25:31Z","timestamp":1696224331000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201903000-00026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002459","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}